NCT00833716View on ClinicalTrials.gov

Effect of Renal Impairment on the Pharmacokinetics of NN9535

PHASE1CompletedINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

February 2, 2009

Primary Completion Date

July 26, 2010

Study Completion Date

July 26, 2010

Conditions
DiabetesDiabetes Mellitus, Type 2Renal Impairment
Interventions
DRUG

semaglutide

10 mg/mL of semaglutide solution for s.c. injection, single dose

Trial Locations (3)

32806

Novo Nordisk Investigational Site, Orlando

33014

Novo Nordisk Investigational Site, Miami

37920

Novo Nordisk Investigational Site, Knoxville

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY